A Curcumin-Loaded Liposomal Thermoresponsive In Situ Nasal Gel for Brain Targeted Antidepressant Therapy
ACS Applied Materials & Interfaces · 2026
DOI: 10.1021/acsami.6c12839 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2026. Verfasst von Ling Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rehabilitation Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu210009, China. Hauptthemen laut MEDLINE: Curcumin, Liposomes, Antidepressive Agents, Brain. Die Arbeit nennt 41 Literaturangaben. Gefördert von: Jiangsu Commission of Health, Natural Science Foundation of Jiangsu Province, Nanjing Municipal Health Bureau.
Abstract (Originalsprache)
Major depressive disorder (MDD) is a chronic and recurrent neuropsychiatric condition that imposes a profound burden on individuals and society. Despite its increasing prevalence, effective therapeutic options that provide rapid, sustained, and well-tolerated relief remain limited. Mounting evidence implicates neuroinflammation, particularly microglial activation, as a critical pathological driver of MDD. Reprogramming reactive microglia toward a neuroprotective phenotype has thus emerged as a promising strategy to ameliorate MDD-related symptoms. Herein, we developed a thermoresponsive in situ gelling intranasal delivery system (TAT-lipo@Cur Gel), which combines TAT-modified liposomes with a Pluronic F127/F68 hydrogel matrix to enhance nose-to-brain transport and prolong mucosal retention of curcumin. Biodistribution studies demonstrated that intranasal administration of TAT-lipo@Cur Gel markedly enhanced curcumin accumulation in the brain. In a chronic unpredictable mild stress (CUMS) mouse model, TAT-lipo@Cur Gel significantly alleviated depressive-like behaviors and restored behavioral performance. Mechanistically, this effect was mediated through suppression of neuroinflammation, as evidenced by reduced expression of pro-inflammatory cytokines, enhanced microglial polarization toward the M2 phenotype, and alleviated astrocytic dysfunction. In summary, our findings establish TAT-lipo@Cur Gel as a safe, non-invasive, and effective intranasal delivery platform for the treatment of MDD. With its excellent biocompatibility, reduced dosing frequency, and shortened treatment duration, this strategy holds great promise for clinical translation in managing MDD and potentially other neuroinflammatory CNS disorders.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rehabilitation Medicine, Zhongda Hospital, Southeast University, Nanjing, Jiangsu210009, China.
- Department of Pharmacology, Jiangsu Provincial Key Laboratory of Critical Care Medicine, School of Medicine, Southeast University, Nanjing, Jiangsu210009, China.
ORCID-Profile: Yanpeng Jia
Förderung
- Jiangsu Commission of Health
- Natural Science Foundation of Jiangsu Province
- Nanjing Municipal Health Bureau
Zitieren
APA
Li, L., Sun, Y., Li, G., Li, Z., Wang, H., Li, Z., Wang, H., & Jia, Y. (2026). A Curcumin-Loaded Liposomal Thermoresponsive In Situ Nasal Gel for Brain Targeted Antidepressant Therapy. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.6c12839
Vancouver
Li L, Sun Y, Li G, Li Z, Wang H, Li Z, et al. A Curcumin-Loaded Liposomal Thermoresponsive In Situ Nasal Gel for Brain Targeted Antidepressant Therapy. ACS Applied Materials & Interfaces. 2026. doi:10.1021/acsami.6c12839
BibTeX
@article{Li2026,
author = {Li, Ling and Sun, Yan and Li, Guanlong and Li, Zhi and Wang, Haocheng and Li, Zhuoyan and Wang, Hongxing and Jia, Yanpeng},
title = {A Curcumin-Loaded Liposomal Thermoresponsive In Situ Nasal Gel for Brain Targeted Antidepressant Therapy},
journal = {ACS Applied Materials & Interfaces},
year = {2026},
doi = {10.1021/acsami.6c12839}
}
EUVIMED